Evidence map›Paper›PMID 33629196›Full record

ArticleJournal of clinical immunology2021

Clinical and Immunological Characteristics of 63 Patients with Chronic Granulomatous Disease: Hacettepe Experience.

Halil Tuna Akar, Saliha Esenboga, Deniz Cagdas, Sevil Oskay Halacli, Begum Ozbek, Karin van Leeuwen, Martin de Boer, Cagman Sun Tan, Yavuz Köker, Dirk Roos and 1 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of clinical immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Halil Tuna AkarFaculty of Medicine, Department of Pediatrics, Hacettepe University, 06100, Ankara, Turkey. halil.tuna.akar@hacettepe.edu.tr.ORCID 0000-0003-1982-8046
Saliha EsenbogaFaculty of Medicine, Department of Pediatrics, Division of Immunology, Hacettepe University, 06100, Ankara, Turkey.
Deniz CagdasFaculty of Medicine, Department of Pediatrics, Division of Immunology, Hacettepe University, 06100, Ankara, Turkey.
Sevil Oskay HalacliInstitute of Children's Health Basic Sciences of Pediatrics Division of Pediatric Immunology, Hacettepe University, 06100, Sihhiye/Ankara, Turkey.
Begum OzbekInstitute of Children's Health Basic Sciences of Pediatrics Division of Pediatric Immunology, Hacettepe University, 06100, Sihhiye/Ankara, Turkey.
Karin van LeeuwenSanquin Research and Landsteiner Laboratory Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Martin de BoerSanquin Research and Landsteiner Laboratory Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Cagman Sun TanInstitute of Children's Health Basic Sciences of Pediatrics Division of Pediatric Immunology, Hacettepe University, 06100, Sihhiye/Ankara, Turkey.
Yavuz KökerFaculty of Medicine, Department of Immunology, Erciyes University, Kayseri, Turkey.
Dirk RoosSanquin Research and Landsteiner Laboratory Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Ilhan TezcanFaculty of Medicine, Department of Pediatrics, Division of Immunology, Hacettepe University, 06100, Ankara, Turkey.
Hacettepe University · TRHacettepe University Hospital · TRSanquin · NLErciyes University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic granulomatous disease (CGD), one of the phagocytic system defects, is the primary immunodeficiency caused by dysfunction of the NADPH oxidase complex which generates reactive oxygen species (ROS), which are essential for killing pathogenic microorganisms, especially catalase-positive bacteria and fungi.

objectiveThe objective of our study was to assess the clinical and laboratory characteristics, treatment modalities, and prognosis of patients with CGD.

methodsWe retrospectively reviewed 63 patients with CGD who have been diagnosed, treated, and/or followed-up between 1984 and 2018 in Hacettepe University, Ankara, in Turkey, as a developing country.

resultsThe number of female and male patients was 26/37. The median age at diagnosis was 3.8 (IQR: 1.0-9.6) years. The rate of consanguinity was 63.5%. The most common physical examination finding was lymphadenopathy (44/63), growth retardation (33/63), and hepatomegaly (27/63). One adult patient had squamous cell carcinoma of the lung. The most common infections were lung infection (53/63), skin abscess (43/63), and lymphadenitis (19/63). Of the 63 patients with CGD, 6 patients had inflammatory bowel disease (IBD). Twelve of the 63 patients died during follow-up. CYBA, NCF1, CYBB, and NCF2 mutations were detected in 35%, 27.5%, 25%, and 12.5% of the patients, respectively.

conclusionWe identified 63 patients with CGD from a single center in Turkey. Unlike other cohort studies in Turkey, due to the high consanguineous marriage rate in our study group, AR form of CGD was more frequent, and gastrointestinal involvement were found at relatively lower rates. The rate of patients who treated with HSCT was lower in our research than in the literature. A majority of the patients in this study received conventional prophylactic therapies, which highlight on the outcome of individuals who have not undergone HSCT.

Indexed as

AdolescentAdultConsanguinityFemaleGranulomatous Disease, ChronicHumansMaleMutationNADPH OxidasesRetrospective StudiesTurkeyYoung AdultNADPH OxidasesChronic Granulomatous Diseasephenotype-genotype correlationprimary immunodeficiency

Identifiers

PMID33629196
OpenAlexW3131384141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.